Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope

Delia Cangini(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Claudio Cerchione(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Paolo Silimbani(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Carla Masini(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Alessandro Cafaro(Ospedale Generale Regionale Francesco Miulli), Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giovanni Martinelli(University of Bologna), Maria Benedetta Giannini(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Andrea Ghelli Luserna di Rorà(Fondazione Pisa)
Minerva Medica
November 1, 2020
10.23736/s0026-4806.20.07018-4
Cited by 10

Related Papers

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
|The Lancet Oncology|2017|493
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
|The Lancet Oncology|2019|486